Silexion Therapeutics Announces Preclinical Data Showing SIL204 Upregulated FAS And Downregulated HLA-G Across Three KRAS-Mutant Pancreatic And NSCLC Cell Lines

Benzinga Newsdesk www.benzinga.com Positive 81.7%

Neg 0% Neu 0% Pos 81.7%

Comments

No comments yet. Be the first!